Table 6

Rate of mTSS non-progression at week 96—observed case

(A) For patients originally randomised to CZP
Week 0 CZP 200 mg Q2W N=138Week 0 CZP 400 mg Q4W N=135Week 0 CZP dose combined N=273
Assessed for progression, n112106218
Rate of non-progression at week 96 (change from Baseline in mTSS ≤0.5)
 Non-progressors, n (%)*98 (87.5)92 (86.8)190 (87.2)
Rate of non-progression at week 96 (change from Baseline in mTSS ≤0)
 Non-progressors, n (%)*82 (73.2)80 (75.5)162 (74.3)
(B) For patients originally randomised to PBO (after 80 or 72 weeks of CZP treatment for PBO patients switching at weeks 16 and 24, respectively)
PBO to CZP at week 16†
N=59
PBO to CZP at week 24†
N=61
PBO to CZP†
N=120
 
Assessed for progression, n5153104
Rate of non-progression over 80 or 72 weeks (change from CZP Baseline in mTSS ≤0.5)—week 96
 Non-progressors, n (%)*48 (94.1)50 (94.3)98 (94.2)
Rate of non-progression over 80 or 72 weeks (change from CZP Baseline in mTSS ≤0)—week 96
 Non-progressors, n (%)*39 (76.5)47 (88.7)86 (82.7)
  • Data are shown for the Randomised Set.

  • *Percentage is based on the number of participants assessed for progression at the visit.

  • PBO patients who withdrew prior to switching to CZP were not considered.

  • CZP, certolizumab pegol; mTSS, modified total Sharp score; PBO, placebo; Q2W, every 2 weeks.